Sinovac’s 10 billion yuan plans include new facility, global HQ in Singapore: Lianhe Zaobao

CHINESE vaccine maker Sinovac Biotech is investing 10 billion yuan (S$2 billion) in a development plan which includes opening a research facility and its international headquarters in Singapore, Lianhe Zaobao reported on Wednesday (Jun 15).

The research facility will develop vaccines for Covid-19 and severe hand, foot and mouth disease, and may be operational as early as within the next few months, said Helen Yang, Sinovac’s Hong Kong general manager and chief business officer.

She shared Sinovac’s plans in an interview with Zaobao last week, while in Singapore to discuss cooperation with local organisations. The 10 billion yuan figure includes opening a research facility in Singapore or collaborating with local research institutes to study new pathogens – though it is unclear exactly how much will be invested in Singapore itself.